NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to LYRA. LYRA was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of LYRA is average, but there are quite some concerns on its profitability. LYRA is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -141.22% | ||
ROE | -2053.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -2.19 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.96 | ||
Quick Ratio | 2.96 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:LYRA (6/12/2025, 9:46:59 AM)
12.5644
-0.94 (-6.93%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 702.65 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 215.04 | ||
P/tB | 215.04 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -141.22% | ||
ROE | -2053.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.96 | ||
Quick Ratio | 2.96 | ||
Altman-Z | -2.19 |